Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.60 |
| ▸ | CNR2 | P34972 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.55 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.55 |
| ▸ | TAS1R2 | Q8TE23 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10246983 | 0.85 | ALDH1A1 (0.48) | CNR1CNR2HTTALDH1A1TSHR | |
| SCHEMBL3388821 | 0.82 | POLB (0.67) | CNR1CNR2HTTALDH1A1TSHR | |
| SCHEMBL3395171 | 0.82 | POLB (0.67) | CNR1CNR2HTTALDH1A1TSHR | |
| SCHEMBL6084180 | 0.81 | NPC1 (0.49) | POLB | |
| SCHEMBL6636985 | 0.81 | ALDH1A1 (0.64) | CNR1CNR2HTTALDH1A1TSHR | |
| SCHEMBL29563786 | 0.80 | HTT (0.65) | HTTALDH1A1TSHRKDM4ETAS1R3 | |
| SCHEMBL8476669 | 0.80 | P2RX7 (0.51) | CNR1CNR2HTTALDH1A1TSHR | |
| SCHEMBL30278603 | 0.80 | HTT (0.61) | CNR1CNR2HTTALDH1A1TSHR | |
| SCHEMBL29572713 | 0.80 | HTT (0.61) | CNR1CNR2HTTALDH1A1TSHR | |
| SCHEMBL28557216 | 0.80 | HTT (0.61) | CNR1CNR2HTTALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| US-6429207-B1 | QUINOXALINE DERIVATIVES EXHIBITING A HIGH DEGREE OF POTENCY AND SELECTIVITY FOR INDIVIDUAL METABOTROPIC GLUTAMATE RECEPTORS (MGLUR) | NPS PHARMACEUTICALS, INC. | 2002-08-06 | — | — | US | claimed |
| US-7053104-B2 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6429207-B1 | QUINOXALINE DERIVATIVES EXHIBITING A HIGH DEGREE OF POTENCY AND SELECTIVITY FOR INDIVIDUAL METABOTROPIC GLUTAMATE RECEPTORS (MGLUR) | NPS PHARMACEUTICALS, INC. | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | GRM2, GRM1, GRM3 | CNR1 91/4885CNR2 123/4885HTT 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.